zirconium Zr 89-labeled atezolizumab

{
  "id": "MLC-T-ONC-017696",
  "term": "zirconium Zr 89-labeled atezolizumab",
  "field": "Oncology and biomedicine",
  "definition": "A radioimmunoconjugate composed of atezolizumab, a humanized, Fc-optimized, monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1) and labeled with the radioisotope zirconium Zr 89, with potential use for assessing PD-L1-expressing tumor cells using positron emission tomography (PET). Upon administration of zirconium Zr 89-labeled atezolizumab, the antibody moiety targets and binds to PD-L1. Following tumor cell uptake, the radioisotope moiety can be visualized using PET. This may result in the quantification of PD-L1-expressing tumor cells, an assessment of the expected response to treatment with atezolizumab as well as selection of patients that would respond to atezolizumab. PD-L1 is overexpressed on many human cancer cell types; PD-L1 binding to programmed cell death 1 (PD-1) on T-cells suppresses the immune system and results in increased immune evasion.",
  "synonyms": [
    "89Zr-MPDL3280A",
    "zirconium Zr 89-labeled MPDL3280A"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/zirconium-zr-89-labeled-atezolizumab/"
}